Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (December 2022)
22 slides from Sanara Medtech's investor presentation, Dec 16, 2022
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview (Nasdaq: SMTI) December 2022 Evidence Based Healing
Slide 2: Disclaimers
Disclaimers v This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements ot
Slide 3: Company Overview
Company Overview . Sanara “ MedTech Evidence Based Healing
Slide 4: Company Highlights
Company Highlights Disruptive surgical company delivering a comprehensive suite of products and technologies across the continuum of care with a focus on lowering costs and improving outcomes Compelling value proposition for all care settings with favorable and improving reimbursement, enabling pote
Slide 5: A Disruptive Surgical Products and Technologies Company
A Disruptive Surgical Products and Technologies Company $300M $13.0M 83% $10M 2022 Market Cap Q3 22 Revenue Q32022GM_ Cash (as of 9/30/22) Zach Fleming appointed CEO Acquisition of Precision Healing Inc. 2020 Scendia Biologics, LLC acquisition Sanara uplists to First month with Nasdaq Capital >$4 mi
Slide 6: Sanara's Six Wound Care and Surgical Site Therapy Focus Areas
Sanara’s Six Wound Care and Surgical Site Therapy Focus Areas Sanara MedTech ivanced Biologics Debrider that leverages the body's own enzymes and moisture Licensed from Rochal Industries Currently under development Products marketed and sold under an exclusive agreement with Cook Biotech Scendia Bio
Slide 7: Large Untapped Addressable Market
Large Untapped Addressable Market Addressable Market Aging population Growing prevalence of health $1.3 + sine .O _ $3.3 conations that can ead Cardiovascular Disease Advanced Dressings Wound Biologics Sanara Diabetes U.S. Market U.S. Market Addressable Market in the U.S. ~6% ~7.5% 5-Yr CAGR") 5-Yr
Slide 8: Surgical and Chronic Wound Disruptive Strategies
Surgical and Chronic Wound Disruptive Strategies Evidence Based Healing
Slide 9: Surgical Wound Disruptive Strategies
Surgical Wound Disruptive Strategies o Surgical Wounds are the largest Medicare co Reduce the economic and clinical burden of spend area in wound care totaling $11.7B post-operative wound complications Aineibaing costorintections) o ~1MArthroplasties performed annually in the o 15.3M surgeries in th
Slide 10: Chronic Wound Care Disruption
Chronic Wound Care Disruption What is the Wound Care Industry Missing Today? Early, accurate diagnosis and intervention Comorbidity recognition and management Education / standard of care for primary providers Access to specialty wound care Product and service innovation Value-based reimbursement mo
Slide 11: SMTI Surgical Division
SMTI Surgical Division - Sanara MedTech Evidence Based Healing
Slide 12: Surgical Products
¢ Sanara Surgical Products weatesh $37M 662") Key Stats as of Q3 2022 28 Ge e States?) aaaS CellerateRX® Surgical FORTIFY TRG® Tissue FORTIFY TEXAGEN® Amniotic Activated Collagen Repair Graft FLOWABLE® ECM Membrane Allograft ae B H nce 4 : 1 i a * Coteratsg, , _ Select Product Offerings BiFORM® Bioa
Slide 13: Company Growth Profile
Company Growth Profile Purchasing Accounts & Approved Quarterly Historical Revenue Growth Hospitals to Use CellerateRX® Revenue by State!) Sin millions $13.0 $9.7 $7.8 $7.0 990 $63 50 900 5.8 $5.0 VNY A Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 3122") Q2'21 Q3'21 was sold in the TTM CellerateRX® “Percenta
Slide 14: SMTI Wound and Virtual Consult Strategy
SMTI Wound and Virtual Consult Strategy Sanara -- MedTech Evidence Based Healing a ce SS ae ccc? oe «© w@ 6 ow + © © * © © ws «+ «© «© ss © 8 =
Slide 15: A Comprehensive Solution for Wound Care
Sanara MedTech A Comprehensive Solution for Wound Care The components of Sanara’s offering are complementary and promote improved outcomes. Sanara Solution Disruption Compared to Current Standard of Care + Designed to quantify key biomarkers that dictate the trajectory of wound healing and identify
Slide 16: Sanara MedTech Portfolio
Sanara MedTech Portfolio Innovative, Comprehensive, Complementary Diagnostics/Treat t Algorithms EMR and Mobile App Virtual Consult Under development + Under development + MGroup Strategies + Wound Care virtual consult services + Licensed in 50 states + Novel and disruptive approach to unmet need in
Slide 17: Research and Development
Research and Development - Sanara MedTech Evidence Based Healing
Slide 18: R&D Divisions: Rochal Technologies & Precision Healing
R&D Divisions: Rochal Technologies & Precision Healing <Rochal ROCHAL TECHNOLOGIES Technologies a PRECISION HEALING commercialization + Product Scale-up + Supplier Development + Biocompatibility Testing + Performance Testing + Stability Testing + Regulatory Support * Clinical Testing + Supply Chain
Slide 19: Pipeline of Anticipated New Product Introductions
Pipeline of Anticipated New Product Introductions a Description Next Gen CellerateRX® and HYCOL® TBD Enhanced hydrolyzed collagen products for targeted wound healing BIASURGE™ Antimicrobial Surgical Wash 2023 Prevent development of surgical site infection and biofilm formation without harming tissue
Slide 20: Financial Overview
Financial Overview « Sanara MedTech Evidence Based Healing
Slide 21: Q3 2022 Financial Highlights
Q3 2022 Financial Highlights Overview + Revenue + For the quarter, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period. + Third quarter revenues included $3.
Slide 22: Questions
22 Questions « Sanara MedTech Evidence Based Healing
Sanara MedTech — Investor Presentation (December 2022) on 6ix